Dr. Servais is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
41 Mall Rd
Burlington, MA 01805Phone+1 781-744-8570Fax+1 781-744-5641
Summary
- Dr. Servais is a board-certified general thoracic surgeon with expertise in diseases of the chest and abdomen. He has particular interest in thoracic oncology (including cancers of the lungs, esophagus, mediastinum, pleura, and chest wall) and esophageal motility disorders (gastroesophageal reflux, paraesophageal/hiatal hernia, and achalasia).
Dr. Servais uses minimally-invasive surgical techniques such as laparoscopy, thoracoscopy or VATS, and has expertise in robotic surgery to minimize pain and post-operative recovery time, while optimizing oncologic and functional outcomes.
Dr. Servais is one of the highest volume robotic thoracic surgeons in the region performing operations such as robotic lobectomy for lung cancer and robotic minimally invasive esophagectomy for esophageal cancer.
Dr. Servais also has expertise in advanced endoscopic and bronchoscopic techniques such as endobronchial ultrasound (EBUS) and per-oral endoscopic myotomy (POEM) for achalasia.
Dr. Servais' research interests include:
-Biomarker discovery and evaluation for early detection and therapeutic response in lung and esophageal cancer
-Evaluation of targeted therapies in thoracic malignancies
-Clinical outcomes research in thoracic surgery
Education & Training
- Beth Israel Deaconess Medical CenterResidency, Thoracic Surgery, 2013 - 2015
- Brigham and Women's Hospital/Children's HospitalFellowship, Thoracic Surgery, 2013 - 2015
- New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 2006 - 2013
- Memorial Sloan Kettering Cancer CenterFellowship, Thoracic Surgical Oncology, 2008 - 2010
- Boston University School of MedicineClass of 2006
- Boston UniversityBA, Medical Program, Summa Cum Laude, 2003
Certifications & Licensure
- NH State Medical License 2015 - Present
- MA State Medical License 2013 - 2026
- NY State Medical License 2007 - 2014
- American Board of Surgery Surgery
- American Board of Thoracic Surgery Thoracic and Cardiac Surgery
Awards, Honors, & Recognition
- John J. Collins Jr., M.D. Award Brigham and Women’s Hospital, Harvard Medical School, 2015
- Distinguished Housestaff Award NewYork-Presbyterian Hospital Alumni Council, Weill Cornell Medical College, 2012
- Finalist 15th Annual C. Walton Lillehei Resident Research Forum, 92nd Annual AATS Meeting, 2012
- Join now to see all
Publications & Presentations
PubMed
- 15 citationsPre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden.Elliot L. Servais, Christos Colovos, Stefan S. Kachala, Prasad S. Adusumilli
Current Protocols in Pharmacology. 2011-09-01 - 13 citationsConversion to Thoracotomy During Thoracoscopic vs Robotic Lobectomy: Predictors and Outcomes.Elliot L Servais, Daniel L Miller, Dylan Thibault, Matthew G Hartwig, Andrzej S Kosinski
The Annals of Thoracic Surgery. 2022-08-01 - 2 citationsThe oncologic efficacy of extended thoracic resections.Sarah Kader, Ammara Watkins, Elliot L Servais
Journal of Surgical Oncology. 2023-02-01
Journal Articles
- Thoracoscopic management of pulmonary metastasesServais EL. Swanson SJ., Thoracic Surgery Clinics, 1/1/2016
- Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinomaKachala SS. Bograd AJ. Villena-Vargas J. Suzuki K. Servais EL. Kadota K. Chou J. Sima CS. Vertes E. Rusch VW. Travis WD. Sadelain M. Adusumilli PS., Clinical Cancer Research, 1/1/2014
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunityAdusumilli PS. Cherkassky L. Villena-Vargas J. Colovos C. Servais E. Plotkin J. Jones DR. Sadelain M., Science Translational Medicine, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Pre-operative Consolidation to Tumor Ratio on Computed Tomography and FDG-PET SUVmax Predict Recurrence after Limited Resection of Early Lung AdenocarcinomaServais EL. Nitadori J. Morales EA. Suzuki K. Bograd AJ. Rizk NP. Downey RJ. Rusch VW. Adusumilli PS., American Association for Thoracic Surgery (AATS), San Francisco, CA, 1/1/2012
- A preclinical mouse model of orthotopic pleural cancer that facilitates noninvasive quantitative monitoring of tumor progression and therapy responseServais EL. Velez MC. Rusch VW. Sadelain M. Adusumilli PS., Cancer Res, AACR Frontiers in Basic Cancer Research Meeting, 1/1/2009
- Intra-operative Pulse OximetryOliveira L, Servais E, Rizk N, Adusumilli P, Bikson M., Journal of Medical Devices, 1/1/2009
- Join now to see all
Lectures
- Mesothelin Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Malignant Pleural Mesothelioma (MPM) Patients: A Potential Mecha...San Francisco, CA - 1/1/2012
- Mesothelin decreases recurrence-free survival in lung adenocarcinoma by imparting an aggressive phenotypeMinneapolis, MN - 1/4./2013
- Mesothelin is a biomarker of tumor aggressiveness and therapy response in malignant pleural mesothelioma (MPM)Washington, DC - 1/6./2010
- Join now to see all
Press Mentions
- #15: CTSNet Beat Podcast: World Society of Cardiovascular & Thoracic SurgeonsMay 11th, 2021
Professional Memberships
- Member
- Fellow
External Links
- YouTube Channelhttps://www.youtube.com/channel/UC3K97i8jD8Di2ysB8mz4SBw
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: